StockData
Immunovant, Inc. logo

Immunovant, Inc. (IMVT) stock

IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30
$33.21−0.07 (-0.21%)

Close on Nov 17, 2026Market cap $6.86BP/E –Yield –

Immunovant total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

No total debt figures for Immunovant

Immunovant has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Immunovant figures

See a number that looks wrong?